Startup profile · funding coverage
Nautilus Biotechnology
Nautilus Biotechnology is developing single-molecule proteomics; went public via SPAC merger in 2021 (NASDAQ: NAUT).
Stage
public
Status
public
Coverage
full
Why Nautilus Biotechnology is interesting
Sujal Patel (Isilon founder) and Stanford’s Parag Mallick aim to quantify the proteome at single-molecule resolution — a16z led Series A and joined the board.
Key facts
- Series A/B: a16z led Series A per a16z announcement
- SPAC (Jun 2021): Listed NASDAQ: NAUT; ~$345M gross proceeds (company IR)
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
Investors in our directory
Funds linked from Nautilus Biotechnology's profile — open a fund page for stage focus and related deal articles.
Industries
Generalist Technology
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Nautilus Biotechnology's financing or category context.
Last updated: 2026-07-24